Development of adverse outcome pathways relevant for the identification of substances having endocrine disruption properties Uterine adenocarcinoma as adverse outcome

Development of adverse outcome pathways relevant for the identification of substances having endocrine disruption properties Uterine adenocarcinoma as adverse outcome

Abstract Development of adverse outcome pathways (AOPs) for uterine adenocarcinoma can provide a practical tool to implement the EFSA‐ECHA Guidance (2018) for the identification of endocrine disruptors in the context of Regulations (EU) No 528/2012 and (EC) No 1107/2009. AOPs can give indications ab...

Full description

Bibliographic Details
Main Authors: EFSA Panel on Plant Protection Products and their Residues (PPR), Antonio F Hernandez‐Jerez, Paulien Adriaanse, Annette Aldrich, Philippe Berny, Tamara Coja, Sabine Duquesne, Andreas Focks, Maurice Millet, Olavi Pelkonen, Silvia Pieper, Aaldrik Tiktak, Christopher J Topping, Anneli Widenfalk, Martin Wilks, Gerrit Wolterink, Karine Angeli, Camilla Recordati, Majorie Van Duursen, Elisa Aiassa, Anna Lanzoni, Alfonso Lostia, Laura Martino, Irene Pilar Munoz Guajardo, Martina Panzarea, Andrea Terron, Marina Marinovich
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:EFSA Journal
Subjects:
Endocrine disruption
uterine adenocarcinoma
adverse outcome pathway (AOP)
EFSA‐ECHA Guidance
Online Access:https://doi.org/10.2903/j.efsa.2023.7744

Internet

https://doi.org/10.2903/j.efsa.2023.7744

Similar Items